Effect Of Invokana And Farxiga For Weight Loss In Diabetics and Non-diabetics | Jonah-Lynne Padigus, PharmD | RxEconsult
Menus

All Health Articles

Invokana and Farxiga for Weight Loss Management Category: Diabetes by - January 31, 2014 | Views: 136478 | Likes: 3 | Comment: 0  

What are the Side Effects of Invokana and Farxiga?

  • Dehydration
  • Frequent urination
  • Fungal infections especially in women
  • Urinary tract infections
  • Low blood glucose (if taken with another diabetes medication)
  • Kidney problems
  • Increase in cholesterol
  • Low blood pressure
  • Hyperkalemia: Increase in blood potassium levels (Invokana)
  • Bladder cancer (Farxiga)

Average Wholesale Price (AWP) for Invokana and Farxiga

Invokana: $11.57 per tablet. 

Farxiga: $11.57 per tablet 

Weighing the Risks and Benefits of Invokana and Farxiga

Invokana and Farxiga have been associated with some favorable effects such as improved glycemic control in patients with type 2 diabetes, weight loss, and lower blood pressure. However, they are also associated with an increase in cholesterol, infections, hyperkalemia, and bladder cancer. Although these medications show evidence of moderate weight reduction, they are not approved for the management of obesity or weight loss. More studies with a longer duration of observation are needed to understand the risks and benefits of Invokana and Farxiga. Those looking for weight loss solutions should talk with their healthcare provider about the possible risks and benefits and established treatments for weight loss.

References

Bristol-Myers Squibb Medical Information (Personal Communication)

Janssen Medical Information and Services (Personal Communication)

Stenlöf K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity, and Metabolism. 2013;15:372-382.

Lavalle-Gonzalez FJ, Januszewicz A, Davidson J. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial. Diabetologia. 2013 Dec;56(12):2582-92.

Wilding J, Mathieu C, Vercruysse F, et al. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes inadequately controlled with metformin and sulfonylurea. Poster presented at: The 72nd Annual Scientific Sessions of the American Diabetes Association (ADA), June 8-12, 2012, Philadelphia, PA.

Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes on metformin and pioglitazone. Poster presented at: The 4th World Congress on Controversies to Consensus in Diabetes, Obesity, and Hypertension (CODHy), November 8-11, 2012, Barcelona, Spain.

Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020-1031.

Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin produces long-term reductions in body weight, waist circumference and total fat mass in patients with type 2 diabetes inadequately controlled on metformin [Poster 751]. Poster presented at: the 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany.

Bolinder J, Ljunggren O, Johansson L et al. Dapagliflozin maintains glycemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2013. Article first published online: 29 AUG 2013. DOI:10.1111/dom.12189.

Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-2224.

Bailey CJ, Iqbal N, T’joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951-959.

Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-2233.

Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med. 2012;156(6):405–415.

Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928-938.

Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473-1478.

Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a randomized, double-blind, placebo-controlled study. Poster presented at: 72nd Annual Scientific Sessions of the American Diabetes Association; June 8-12, 2012; Philadelphia, PA; Poster 1071-P.

 


For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2021 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap